Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Evaluation of Novel Antigen-Based Rapid Detection Test for the Diagnosis of SARS-CoV-2 in Respiratory Samples
23 Pages Posted: 14 Apr 2020
More...Abstract
Background: In the context of the COVID-19 pandemic, the development and validation of rapid and easy-to-perform diagnostic methods are of high priority to enable the required testing scale up in most countries. We evaluated a novel rapid antigen detection test (RDT) for SARS-CoV-2 in respiratory samples.
Method: sA new fluorescence immunochromatographic SARS-CoV-2 antigen detection test (Bioeasy Biotechnology Co., Shenzhen, China) was evaluated in nasophayngeal (NP) and oropharyngeal (OP) swabs from patients with suspected COVID-19 in Santiago, Chile. Diagnostic accuracy was determined in comparison to SARS-CoV-2 real time (RT)-PCR, using the same material (universal transport medium with NP and OP swab).
Findings: A total of 127 samples were included. The median patients’ age was 38 years (IQR 29·5–44), 53·5% were male, and 93·7% were in the first week after symptom onset. Among 82 RT-PCR positive specimens, 77 were correctly detected by RDT. All 45 RT-PCR negative samples were correctly identified. The overall sensitivity and specificity of the RDT were 93·9% (CI95% 86·5–97·4) and 100% (CI95% 92·1–100), respectively, with a diagnostic accuracy of 96·1% and Kappa coefficient of 0·9. Sensitivity was significantly higher in samples with increased viral loads.
Interpretation: The antigen-based immunofluorescence RDT showed a high sensitivity and specificity in respiratory samples obtained from patients who mainly presented during the first week of COVID-19, despite the use of a non-validated sample. The assay was easy to use and provided results in a timely manner. It has the potential to become an important tool for early diagnosis of SARS-CoV-2, particularly in situations with limited access to molecular methods.
Funding Statement: This work did not receive funding.
Declaration of Interests: All authors declare no competing interests.
Ethics Approval Statement: The study was approved by the local Institutional Review Board (Comité Etico Científico, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile) and need for informed consent was waived.
Keywords: coronavirus; SARS-CoV-2; COVID-19; diagnosis; rapid diagnostic test; antigen
Suggested Citation: Suggested Citation